454 related articles for article (PubMed ID: 15937303)
1. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias.
Koeppe RA; Gilman S; Joshi A; Liu S; Little R; Junck L; Heumann M; Frey KA; Albin RL
J Nucl Med; 2005 Jun; 46(6):936-44. PubMed ID: 15937303
[TBL] [Abstract][Full Text] [Related]
2. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.
Koeppe RA; Gilman S; Junck L; Wernette K; Frey KA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S67-76. PubMed ID: 18632004
[TBL] [Abstract][Full Text] [Related]
3. Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment.
Albin RL; Koeppe RA; Burke JF; Giordani B; Kilbourn MR; Gilman S; Frey KA
Arch Neurol; 2010 Apr; 67(4):440-6. PubMed ID: 20385910
[TBL] [Abstract][Full Text] [Related]
4. Impact of molecular imaging on the diagnostic process in a memory clinic.
Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
[TBL] [Abstract][Full Text] [Related]
5. Evaluating 2-[
Gjerum L; Frederiksen KS; Henriksen OM; Law I; Bruun M; Simonsen AH; Mecocci P; Baroni M; Dottorini ME; Koikkalainen J; Lötjönen J; Hasselbalch SG
Neuroimage Clin; 2020; 27():102267. PubMed ID: 32417727
[TBL] [Abstract][Full Text] [Related]
6. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies.
Lim SM; Katsifis A; Villemagne VL; Best R; Jones G; Saling M; Bradshaw J; Merory J; Woodward M; Hopwood M; Rowe CC
J Nucl Med; 2009 Oct; 50(10):1638-45. PubMed ID: 19759102
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
Foster NL; Heidebrink JL; Clark CM; Jagust WJ; Arnold SE; Barbas NR; DeCarli CS; Turner RS; Koeppe RA; Higdon R; Minoshima S
Brain; 2007 Oct; 130(Pt 10):2616-35. PubMed ID: 17704526
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
[TBL] [Abstract][Full Text] [Related]
9. Syndrome-specific patterns of regional cerebral glucose metabolism in posterior cortical atrophy in comparison to dementia with Lewy bodies and Alzheimer's disease--a [F-18]-FDG pet study.
Spehl TS; Hellwig S; Amtage F; Weiller C; Bormann T; Weber WA; Hüll M; Meyer PT; Frings L
J Neuroimaging; 2015; 25(2):281-288. PubMed ID: 24593796
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis in Alzheimer's disease and dementia with Lewy bodies via VMAT2 and amyloid imaging.
Villemagne VL; Okamura N; Pejoska S; Drago J; Mulligan RS; Chételat G; O'Keefe G; Jones G; Kung HF; Pontecorvo M; Masters CL; Skovronsky DM; Rowe CC
Neurodegener Dis; 2012; 10(1-4):161-5. PubMed ID: 22261520
[TBL] [Abstract][Full Text] [Related]
11. ¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Smailagic N; Vacante M; Hyde C; Martin S; Ukoumunne O; Sachpekidis C
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010632. PubMed ID: 25629415
[TBL] [Abstract][Full Text] [Related]
12. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
Shea YF; Ha J; Lee SC; Chu LW
Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
[TBL] [Abstract][Full Text] [Related]
13. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias.
Mosconi L; Tsui WH; Herholz K; Pupi A; Drzezga A; Lucignani G; Reiman EM; Holthoff V; Kalbe E; Sorbi S; Diehl-Schmid J; Perneczky R; Clerici F; Caselli R; Beuthien-Baumann B; Kurz A; Minoshima S; de Leon MJ
J Nucl Med; 2008 Mar; 49(3):390-8. PubMed ID: 18287270
[TBL] [Abstract][Full Text] [Related]
14. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients.
Rostomian AH; Madison C; Rabinovici GD; Jagust WJ
J Nucl Med; 2011 Feb; 52(2):173-9. PubMed ID: 21233181
[TBL] [Abstract][Full Text] [Related]
15. Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer's dementia.
Spehl TS; Frings L; Hellwig S; Weiller C; Hüll M; Meyer PT; Amtage F
Clin Nucl Med; 2015 Jan; 40(1):e27-33. PubMed ID: 25140560
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography imaging in dementia.
Herholz K; Carter SF; Jones M
Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
[TBL] [Abstract][Full Text] [Related]
17. Early differential diagnosis between Alzheimer's disease and dementia with Lewy bodies: Comparison between (18)F-FDG PET and (123)I-IMP SPECT.
Chiba Y; Iseki E; Fujishiro H; Ota K; Kasanuki K; Suzuki M; Hirayasu Y; Arai H; Sato K
Psychiatry Res Neuroimaging; 2016 Mar; 249():105-12. PubMed ID: 26857415
[TBL] [Abstract][Full Text] [Related]
18. The Cingulate Island Sign on FDG-PET vs. IMP-SPECT to Assess Mild Cognitive Impairment in Alzheimer's Disease vs. Dementia with Lewy Bodies.
Chiba Y; Fujishiro H; Iseki E; Kasanuki K; Sato K
J Neuroimaging; 2019 Nov; 29(6):712-720. PubMed ID: 31199036
[TBL] [Abstract][Full Text] [Related]
19. Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT.
Tripathi M; Tripathi M; Damle N; Kushwaha S; Jaimini A; D'Souza MM; Sharma R; Saw S; Mondal A
Neuroradiol J; 2014 Feb; 27(1):13-21. PubMed ID: 24571830
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing.
Gilman S; Koeppe RA; Little R; An H; Junck L; Giordani B; Persad C; Heumann M; Wernette K
Exp Neurol; 2005 Feb; 191 Suppl 1():S95-S103. PubMed ID: 15629765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
